Sin­gu­lar fo­cus on ROR1 earns Velos­Bio $137M to fund PhI ADC and oth­er pro­grams

Years af­ter sell­ing Ac­er­ta to As­traZeneca for $7 bil­lion, large­ly on the promise of its BTK in­hibitor, Dave John­son has once again gath­ered hefty fi­nan­cial sup­port be­hind a new can­cer tar­get.

Ma­trix Cap­i­tal Man­age­ment and Sur­vey­or Cap­i­tal are lead­ing a $137 mil­lion round for Velos­Bio, which has re­cent­ly be­gun a Phase I study for its lead an­ti­body-drug con­ju­gate tar­get­ed against ROR1. John­son took up the CEO post in Oc­to­ber 2018.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.